These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 14507800)

  • 1. The use of brain natriuretic peptide as a screening test for left ventricular systolic dysfunction- cost-effectiveness in relation to open access echocardiography.
    Sim V; Hampton D; Phillips C; Lo SN; Vasishta S; Davies J; Penney M
    Fam Pract; 2003 Oct; 20(5):570-4. PubMed ID: 14507800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrospective analysis of the cost-effectiveness of using plasma brain natriuretic peptide in screening for left ventricular systolic dysfunction in the general population.
    Nielsen OW; McDonagh TA; Robb SD; Dargie HJ
    J Am Coll Cardiol; 2003 Jan; 41(1):113-20. PubMed ID: 12570953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study.
    Vasan RS; Benjamin EJ; Larson MG; Leip EP; Wang TJ; Wilson PW; Levy D
    JAMA; 2002 Sep; 288(10):1252-9. PubMed ID: 12215132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective study in search of an optimal B-natriuretic peptide level to screen patients for cardiac dysfunction.
    Atisha D; Bhalla MA; Morrison LK; Felicio L; Clopton P; Gardetto N; Kazanegra R; Chiu A; Maisel AS
    Am Heart J; 2004 Sep; 148(3):518-23. PubMed ID: 15389242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Occurrence and predictors of left ventricular systolic dysfunction at hospital discharge and in long-term follow-up after acute myocardial infarction treated with primary percutaneous coronary intervention.
    Świątkiewicz I; Magielski P; Woźnicki M; Gierach J; Jabłoński M; Fabiszak T; Koziński M; Sukiennik A; Bronisz A; Kubica J
    Kardiol Pol; 2012; 70(4):329-40. PubMed ID: 22528703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Community screening for left ventricular systolic dysfunction using plasma and urinary natriuretic peptides.
    Ng LL; Loke IW; Davies JE; Geeranavar S; Khunti K; Stone MA; Chin DT; Squire IB
    J Am Coll Cardiol; 2005 Apr; 45(7):1043-50. PubMed ID: 15808762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility of B-type natriuretic peptide (BNP) as a screen for left ventricular dysfunction in patients with diabetes.
    Epshteyn V; Morrison K; Krishnaswamy P; Kazanegra R; Clopton P; Mudaliar S; Edelman S; Henry R; Maisel A
    Diabetes Care; 2003 Jul; 26(7):2081-7. PubMed ID: 12832317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction.
    Heidenreich PA; Gubens MA; Fonarow GC; Konstam MA; Stevenson LW; Shekelle PG
    J Am Coll Cardiol; 2004 Mar; 43(6):1019-26. PubMed ID: 15028361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of previously undiagnosed left ventricular systolic dysfunction: community screening using natriuretic peptides and electrocardiography.
    Ng LL; Loke I; Davies JE; Khunti K; Stone M; Abrams KR; Chin DT; Squire IB
    Eur J Heart Fail; 2003 Dec; 5(6):775-82. PubMed ID: 14675856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Validity and usefulness of B-type natriuretic peptide (BNP) for early detection of left ventricular dysfunction in high-risk patients in primary care].
    Lobos Bejarano JM; Horrillo García C; González-González AI; Castellanos Rodríguez A; Díaz Sánchez S; Castellanos Maroto J; Rodriguez-Barrientos R; García-Fernández MA
    Aten Primaria; 2012 Jan; 44(1):13-9. PubMed ID: 21636177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Possible role of BNP for an early diagnosis of asymptomatic left ventricular dysfunction: a retrospective study.
    De Vecchis R; Esposito C; Ariano C; Di Biase G
    Minerva Cardioangiol; 2014 Apr; 62(2):147-59. PubMed ID: 24686994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. QRS prolongation on surface ECG and brain natriuretic peptide as indicators of left ventricular systolic dysfunction.
    Krüger S; Filzmaier K; Graf J; Kunz D; Stickel T; Hoffmann R; Hanrath P; Janssens U
    J Intern Med; 2004 Feb; 255(2):206-12. PubMed ID: 14746557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive value of B-type natriuretic peptides in detecting latent left ventricular diastolic dysfunction in beta-thalassemia major.
    Kremastinos DT; Hamodraka E; Parissis J; Tsiapras D; Dima K; Maisel A
    Am Heart J; 2010 Jan; 159(1):68-74. PubMed ID: 20102869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B-type natriuretic peptide level in the diagnosis of asymptomatic diastolic dysfunction.
    Karaca I; Gülcü E; Yavuzkir M; Dağli N; Ilkay E; Ozbay Y; Işik A; Arslan N
    Anadolu Kardiyol Derg; 2007 Sep; 7(3):262-7. PubMed ID: 17785213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Electrocardiogram and B-type natriuretic peptide as screening tools for left ventricular systolic dysfunction in a population-based sample of 75-year-old men and women.
    Hedberg P; Lönnberg I; Jonason T; Nilsson G; Pehrsson K; Ringqvist I
    Am Heart J; 2004 Sep; 148(3):524-9. PubMed ID: 15389243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biochemical detection of left-ventricular systolic dysfunction.
    McDonagh TA; Robb SD; Murdoch DR; Morton JJ; Ford I; Morrison CE; Tunstall-Pedoe H; McMurray JJ; Dargie HJ
    Lancet; 1998 Jan; 351(9095):9-13. PubMed ID: 9433422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Screening for asymptomatic left ventricular systolic dysfunction in high-risk patients. Preliminary experience with a program based on the use of ECG and natriuretic peptide].
    Tarantini L; Cioffi G; Di Lenarda A; Valle R; Pulignano G; Del Sindaco D; Frigo G; Soravia G; Tessier R; Catania G
    G Ital Cardiol (Rome); 2008 Dec; 9(12):835-43. PubMed ID: 19119693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of plasma B type natriuretic peptide measurement for heart disease screening in a Japanese population.
    Nakamura M; Endo H; Nasu M; Arakawa N; Segawa T; Hiramori K
    Heart; 2002 Feb; 87(2):131-5. PubMed ID: 11796549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction.
    Maisel AS; Koon J; Krishnaswamy P; Kazenegra R; Clopton P; Gardetto N; Morrisey R; Garcia A; Chiu A; De Maria A
    Am Heart J; 2001 Mar; 141(3):367-74. PubMed ID: 11231433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [BNP-guided therapy optimizes the timing of discharge and the medium term risk stratification in patients admitted for congestive heart failure].
    Valle R; Aspromonte N; Carbonieri E; De Michele G; Di Tano G; Giovinazzo P; Cioè R; Di Giacomo T; Milani L; Noventa F; Chiatto M
    Monaldi Arch Chest Dis; 2007 Sep; 68(3):154-64. PubMed ID: 18361212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.